Cagrilintide 5mg / Semaglutide 5mg research blend for laboratory studies. Pharmaceutical-grade dual peptide for in-vitro research only. Not for human consumption.
Cagrilintide 5mg / Tirzepatide 10mg research blend for laboratory studies. Pharmaceutical-grade peptides for in-vitro research only. Not for human consumption.
Oral semaglutide is a 31-amino acid GLP-1 receptor agonist with engineered modifications (Aib8, C-18 fatty di-acid, Lys34Arg) enabling oral bioavailability via SNAC absorption enhancement technology. Research demonstrates glycemic control comparable to injectable GLP-1 agonists with 15.1% weight loss (50mg dose, OASIS-1 trial).
Triple monoamine reuptake inhibitor (TRI) potently inhibiting presynaptic reuptake of serotonin, norepinephrine, and dopamine with IC₅₀ values: NET 1.7-3.2 nM, SERT 11 nM, DAT 8.0-65 nM
Produces approximately twice the weight loss of currently marketed anti-obesity medications; Phase II trials: 9-11% body weight reduction over 24 weeks at therapeutic doses (0.5-1.0 mg)
FDA orphan drug designation for Tesomet (tesofensine + metoprolol) in Prader-Willi syndrome (March 2021) and hypothalamic obesity (July 2021); exceptionally long half-life (~9 days) enabling once-daily dosing
